Eli Lilly to double its manufacturing capacity for Mounjaro as it faces financial headwinds going into 2023 — report
Eli Lilly is facing several financial headwinds going into next year, spurred by the drying up of Covid-19 antibody sales and supply constraints, according to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.